GLP, which had about $80 billion in assets under management as of end-December, plans to begin meeting select investors in ...

Certain tortillas are now being marketed as ‘GLP-1 friendly.’ What does that even mean? - While a ‘GLP-1 friendly’ label may ...

GLP-1 weight-loss and diabetes drugs may have a future role in cancer prevention and treatment, according to new research highlighted by Citi ahead of the 2026 American Society of Clinical Oncology ...

Medicare will expand coverage for GLP-1 drugs. Here's how this new development will affect you if you are on Medicare ...

Research found that the weight-loss medications may reduce the spread of several obesity-related cancers, including lung, ...

GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week ...

CLEVELAND, Ohio — Eligible Americans on Medicare may be able to get a month’s supply of some GLP-1 drugs for $50 from July 1 through the end of the year, the Centers for Medicare & Medicaid Services ...

Eli Lilly has expanded its glucagon-like peptide (GLP) portfolio in an intriguing direction by licensing a phase 2-stage GLP-2 agonist from Hanmi Pharm. The Korean biotech has already taken the drug, ...

As the popularity of weight-loss drugs continues to boom, it has opened the door for scammers eager to dupe people into buying fake versions of the medications. The Better Business Bureau has issued a ...

Learn who qualifies for Medicare’s GLP-1 Bridge, when $50 Wegovy and Zepbound access begins, and key rules beneficiaries need to know before July 2026.

That means millions more Americans may get access to Lilly’s new GLP-1 pill Foundayo or the GLP-1 injection Zepbound.